A Qualitative Study to Assess US Patient Preferences between new Transdermal System and Injectable Anabolic Therapies for Osteoporosis Treatment.

Autor: Beaudart C; Department of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, Duboisdomein 30, 6229, GT, Maastricht, the Netherlands. c.beaudart@maastrichtuniversity.nl., Silverman S; Cedars-Sinai, Los Angeles, CA, USA.; University of California Los Angeles Medical Center, University of California Los Angeles, Los Angeles, CA, USA., Gold DT; Department of Psychiatry & Behavioral Sciences, Duke University Medical Center, Durham, NC, USA., Williams SA; Radius Health, Inc., Boston, MA, USA., Weiss R; Radius Health, Inc., Boston, MA, USA., Hiligsmann M; Department of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, Duboisdomein 30, 6229, GT, Maastricht, the Netherlands.
Jazyk: angličtina
Zdroj: Archives of osteoporosis [Arch Osteoporos] 2022 Apr 04; Vol. 17 (1), pp. 57. Date of Electronic Publication: 2022 Apr 04.
DOI: 10.1007/s11657-022-01075-z
Abstrakt: US patients with osteoporosis included in three focus groups identified efficacy, safety, cost, and convenience as important attributes of treatment when choosing between anabolic therapies with high stated preference for the solid Microstructured Transdermal System.
Objective: The current study evaluated patient perspective and relative importance of treatment attributes of in-home daily self-administration of abaloparatide-solid Microstructured Transdermal System (sMTS) compared with other anabolic agents (i.e. in-home daily subcutaneous self-injections, and monthly subcutaneous injections at doctor office) among a group of US patients with osteoporosis.
Methods: The current study included systematic literature reviews, experts' consultation and three online patients focus groups (n=27), including patients ≥50 years of age at high risk for fracture. Nominal Group Technique was used by asking patients to (1) Individually identify characteristics that would be important for them when choosing between anabolic treatments, (2) Share ideas and discuss perspectives with other patients, (3) Review additional attributes generated from a systematic literature review, (4) Select and rank individually the 7 most important characteristics from the list and (5) Report their acceptability and stated preference ranking between the three treatment options.
Results: Twenty women and 7 men with a mean age of 65 (range 51-85 years) participated in the focus groups. Twenty-four treatment characteristics were identified through focus groups and literature review. Efficacy, safety, out-of-pocket costs, strength of evidence and the option to self-administer were ranked as the most important attributes. The majority of patients stated preference for a daily sMTS if prescribed by their doctor.
Conclusions: This study revealed that efficacy, safety, costs, and convenience are important attributes of osteoporosis treatment for US patients at high risk for fractures when choosing between anabolic therapies, with a high stated preference for sMTS.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz: